Actualités

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.

Bristol Myers Squibb (NYSE:BMY) has secured approval from the European Commission for the use of Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) as a first-line treatment for adults and adolescents aged 12 years and older with previously untreated Stage III or Stage IV classical Hodgkin lymphoma. The decision introduces the first immunotherapy-based treatment regimen approved in the European Union for patients newly diagnosed with advanced classical Hodgkin

AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q1, starting with Bristol-Myers Squibb (NYSE:BMY).

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Illumina (NasdaqGS:ILMN) has launched new oncology research tools, including the fully automated fireflyGO platform for targeted cancer workflows. The company has expanded its research panels for solid and blood cancers, aiming to support more precise tumor profiling. Illumina introduced its first distributed whole genome MRD research kit, validated with partners such as Mayo Clinic and highlighted with Bristol Myers Squibb at ASCO. For investors tracking Illumina, this update adds product...

Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced treatment.

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.

Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 12 Most Undervalued Stocks to Invest In. On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. Bristol Myers Squibb said the collaboration moves its AI use beyond conversational tools […]

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion in assets and a 0.06% expense ratio. SCHD currently yields roughly 3.3% and has delivered a 20% year-to-date price return on top of income, outpacing the S&P 500. The key question is whether the distribution ... SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.

BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.

PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.

Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) plans to present extensive new clinical data at the 2026 ASCO Annual Meeting. The company will share more than 60 scientific disclosures, including 19 oral presentations across oncology programs. Late-breaking Phase 3 data, including SUCCESSOR-2 for mezigdomide and izalontamab brengitecan, will be highlighted. The updates cover multiple myeloma, lymphoma, breast and lung cancers, and several emerging oncology mechanisms. For investors tracking NYSE:BMY, this...

With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

With an annual dividend yield of 4.25%, Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on May 20 that it was partnering with Anthropic to deploy […]

The numbers don't tell the full story with this big pharma stock.

Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best ARK Stocks to Buy Right Now. On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success […]

As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.